Hamburg, NJ, United States of America

Christian Jacques

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christian Jacques: Innovator in Multiple Myeloma Treatment

Introduction

Christian Jacques is a notable inventor based in Hamburg, NJ (US). He has made significant contributions to the field of medicine, particularly in the treatment of multiple myeloma. His innovative approach combines immunomodulatory compounds with antibodies to enhance patient outcomes.

Latest Patents

Christian Jacques holds a patent for "Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies." This patent discloses specific methods for treating, preventing, and managing multiple myeloma. The methods involve administering an immunomodulatory compound, such as lenalidomide or pomalidomide, alongside an anti-CS1 antibody, like elotuzumab, particularly in patients who have undergone autologous stem cell transplantation. He has 1 patent to his name.

Career Highlights

Christian Jacques is associated with Celgene Corporation, a leading biopharmaceutical company known for its innovative therapies. His work at Celgene has focused on advancing treatment options for patients suffering from multiple myeloma, showcasing his commitment to improving healthcare outcomes.

Collaborations

Christian has collaborated with esteemed colleagues, including Anjan Thakurta and Mohamed Hussein. These partnerships have contributed to the development of groundbreaking treatments in the field of oncology.

Conclusion

Christian Jacques is a pioneering inventor whose work in the treatment of multiple myeloma has the potential to change lives. His innovative methods and dedication to research exemplify the spirit of invention in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…